Synergism Between Sequential Immunotherapy and Radiotherapy in A Malignant Pleural Mesothelioma Patient
Malignant Pleural Mesothelioma (MPM) is a highly invasive tumor that is linked to previous asbestos exposure. Combined multimodality treatment, i.e induction chemotherapy followed by surgery, is standard of care in highly selected patients. Platinum-doublet chemotherapy is the first choice for inoperable or advanced disease. There are no good recommendations for second-line treatment due to the lack of a clear survival benefit. Chest wall invasion is common and radiotherapy is used for pain control. We report the case of an MPM patient that showed a remarkable response through the combination of radiotherapy and immunotherapy. This case illustrates that despite failure of single-agent checkpoint inhibition, the combination of radiotherapy and immunotherapy has the potential to overcome checkpoint-inhibitor resistance in MPM.